IRD 8-K 2026-11-10

Opus Genetics, Inc. (IRD) 8-K dated 2026-11-10 — accession 0001628280-26-072493.

Opus Genetics, Inc. (IRD) is a biotechnology company listed on US.

IRD: Opus Genetics Announces Financial Results for

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported IRD revenue for 2025-12-31 was $14.2M. Net income was -$49.6M. Revenue was up 29.1% from 2024-12-31 to 2025-12-31. IRD currently screens at market cap $35.7M.

Not investment advice. The IRD SEC hub lists recent forms. The stock page is the research view.